Allergan recruits profile pic experts for latest Kybella blitz

Career counselor Maggie Mistal and photographer Peter Hurley discuss the importance of profile pictures for a new Kybella campaign from Allergan.

In its latest push for chin-fat buster Kybella, Allergan is turning the conversation toward a topic that can be a sensitive one for self-conscious consumers: social media profile pictures.

The company has pulled together tips from a pair of social profile experts on how to look your best, both physically and professionally, in the photos you share--beyond using Kybella to treat submental fullness, a condition that doesn’t always respond to weight loss, Allergan notes.

Photographer Peter Hurley, for one, recommends specific strategies for taking your ideal shot--such as “squinching,” a technique he developed to help people look more attractive and approachable. It involves bringing your lower eyelids up slightly toward your pupils, and he suggests practicing it in a mirror.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Career counselor and podcast host Maggie Mistal’s advice? If you want to capture the attention of a hiring manager, go it alone. Avoid cropping other people out of your photos, which never looks professional, she contends. Avoid distracting backgrounds such as tourist landmarks, too.

“The extraordinary reach of social media means our image is everywhere these days, but unfortunately I have a lot clients tell me they actually avoid appearing in social media photos because they’re unhappy or feel self-conscious about the way they look in these images,” Hurley said in a statement.

Allergan, of course, has a product it believes can ease some of those negative feelings by eliminating double chin. And it hasn’t been shy about pushing the new launch, which already boasts an inheritance-focused DTC campaign and a partnership with Khloé Kardashian.

So far, physicians seem to like the product, which bodes well for the Dublin drugmaker.  “Patient results have been encouraging and feedback overall positive,” RBC Capital Markets’ Randall Stanicky wrote in a recent note to clients.

And another good sign: Docs “indicated there was interest and early use among injectable-naive patients and importantly men”--two areas where he sees potential for expansion and cross-selling across Allergan’s facial aesthetics portfolio.

Overall, Stanicky expects sales to reach about $500 million in 2021, with longer-term growth following that benchmark. Allergan itself has said it the med could measure up to blockbuster Botox in the future. In the meantime, though, consensus estimates are more measured, predicting $442 million at the 2021 mark.

- read Allergan's release

Related Articles:
Proud Kybella users bare their fat-free chins in Allergan's new DTC ad push
Bra-line fat: It's a thing, and Allergan's studying Kybella as a remedy
Allergan plots DTC, label expansions for chin-fat buster Kybella
With Allergan's Kybella campaign, Khloé Kardashian follows sister Kim into pharma land
Can Allergan make double-chin drug pay off? Maybe, but slowly, analysts say
Allergan extends deal spree with $2.1B Kythera buyout


Suggested Articles

An injection that's under FDA priority review as a monthly HIV therapy can suppress the virus even if given every two months, a phase 3 has shown.

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.